预约演示
更新于：2026-01-10
Hydrocodone bitartrate
重酒石酸氢可酮
更新于：2026-01-10
概要
基本信息
简介Hydrocodone bitartrate是一种阿片类止痛药，通常被称为“氢可酮”。其化学名为4,5(alpha)-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5) 或morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5 alpha)-, [R (R*, R*)]-2,3-dihydroxybutanedioate (1:1),hydrate (2:5)。氢可酮是美国用于急性和慢性疼痛的最常用药物，2012年的处方量超过1.35亿。由于其易获取性和滥用模式，氢可酮被认为是引起滥用和误用的阿片类药物的主要驱动力。其机制是通过刺激阿片受体发挥镇痛作用。 |
药物类型 小分子化药 |
别名 酒石酸氢可酮、AFI-001、ATLP-03 + [9] |
作用方式 激动剂 |
作用机制 Opioid receptors激动剂(阿片样受体激动剂) |
在研适应症 |
原研机构- |
在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2013-10-25), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H29NO10 |
InChIKeyZICRJLQTAUVSDU-NSJZFRMTSA-N |
CAS号34195-34-1 |
关联
41
项与 重酒石酸氢可酮 相关的临床试验ChiCTR2500113802
The Effect of Hydrocodone Combined with Low-Dose Esketamine on Postoperative Recovery Quality in Patients Undergoing Laparoscopic Hysterectomy
ChiCTR2500110695
Study on the analgesic efficacy and postoperative recovery quality of oxycodone hydrochloride injection combined with TAP block under accelerated rehabilitation surgery mode for gynecological laparoscopic surgery in obese patients
ChiCTR2500113704
A prospective, multicenter, randomized, crossover controlled clinical trial evaluating the efficacy and patient preference for Chinese-made and imported sustained-release hydrocodone hydrochloride tablets versus sustained-release oxycodone hydrochloride tablets in cancer pain patients.
100 项与 重酒石酸氢可酮 相关的临床结果
登录后查看更多信息
100 项与 重酒石酸氢可酮 相关的转化医学
登录后查看更多信息
100 项与 重酒石酸氢可酮 相关的专利（医药）
登录后查看更多信息
1,429
项与 重酒石酸氢可酮 相关的文献（医药）2026-02-01Gynecologic Oncology Reports
Abdominal wall blocks in robotic hysterectomy for endometrial cancer are associated with a modest reduction in the frequency of patients receiving post-operative intravenous opioids
Article
作者: Gabriel, Rodney ; Plaxe, Steven ; Corbetta, Francesca ; Saenz, Cheryl ; Binder, Pratibha ; McHale, Michael ; Eskander, Ramez ; Hill, Breana ; Soylu, H Meryem ; Wilson, Elise ; Bondre, Ioana
Objective:
To evaluate the association of abdominal wall blocks at the time of robotic hysterectomy performed for endometrial cancer (EC) with in-hospital post-operative opioids.
Methods:
We performed a retrospective cohort study of patients in the Vizient database who had robotic hysterectomy for EC between January 2019 and December 2022. The exposure was any block coded separate from the surgery, and the primary outcomes were any IV/oral opioid. Fentanyl was excluded due to frequent intra-op use. Length of stay (LOS) and direct cost were compared. The association between block and opioid use was assessed via risk ratio. The quantity of each opioid was expressed in standard resource units (SRU) - a metric used to standardize the consumption of medications across facilities.
Results:
Three hundred and twenty of the 9062 patients (3.5 %) had a block and 8,742 (96.5 %) did not. Blocks were performed at 66 (20.4 %) hospitals. 184 patients (57.5 %) in the block group received an IV opioid vs 5,890 (67.4 %) of the patients without a block (RR 0.85, 95 % CI 0.77-0.94, p < 0.001). Patients who received blocks were less likely to receive IV (52.5 % vs 64.8 %, RR 0.81, 95 % CI 0.73-0.89, p < 0.001) and oral hydromorphone (6.9 % vs 3.9 %, RR 2.53, 95 % CI 1.68-3.81, p < 0.001) and more likely to receive oral hydrocodone/acetaminophen (11.3 % vs 0.88 %, RR 12.77, 95 % CI 8.73-18.67, p < 0.001).
Conclusion:
Blocks are infrequently performed and are associated with a modest reduction in the number of patients receiving post-op IV opioids. We found no difference in LOS or cost. Limitations include lack of detail regarding type of block, anesthetic, and phase of care.
2026-01-01JOURNAL OF CHROMATOGRAPHY A
Surrogate optimization with multivariate adaptive regression splines for supercritical fluid extraction-supercritical fluid chromatography hyphenated to tandem mass spectrometry
Article
作者: Black, Destini ; Sood, Jaivardhan ; Bhakta, Niray ; Yang, Yujing ; Schug, Kevin A ; Chen, Victoria C P ; Rosenberger, Jay
When analyzing complex mixtures, on-line extraction techniques improve reproducibility and robustness in comparison to bench extractions, but they often face challenges due to the complexity of method development processes. In this study, we introduce a new optimization strategy for on-line extraction that uses a multivariate adaptive regression splines (MARS)-based surrogate optimization approach to optimize five key parameters associated with supercritical fluid extraction: flow rate, modifier concentration, back-pressure, static time, and dynamic time. A commercial on-line supercritical fluid extraction - supercritical fluid chromatography - mass spectrometry instrument was used. A mixture of 12 pharmaceuticals were selected; structural diversity metrics were encoded and used for subset selection and to evaluate molecular similarity. Hydrocodone was chosen arbitrarily as the primary analyte for parameter optimization and the primary reference for molecular similarity. The performance of the 11 other compounds were monitored. A ratio of peak area to full-width at half maximum (A/W) was the primary performance metric, to reflect both extraction efficiency and chromatographic efficiency through the optimization process. The MARS surrogate optimization algorithm identified optimal parameters within 20 runs, greatly reducing experimental effort and achieving a relative standard deviation of 3 %. An additional composite performance metric was devised to include peak symmetry and reproducibility, which further lowered variability to 2 % and reached a best-known solution in just 16 runs. Compared to traditional methods like central composite design, surrogate optimization converges faster and explores the parameter space more effectively. Surrogate optimization using MARS provides a new and efficient framework for optimizing complex extraction processes.
2025-12-10CLINICAL SCIENCE
Blood pressure reduction and anti-inflammatory macrophage augmentation attenuate uterine immune dysregulation and inflammation in mice with salt-sensitive hypertension
Article
作者: Smith, Hannah L. ; Navaneethabalakrishnan, Shobana ; Cardenas, Alyssa ; Peterson, Gabriella C. ; Montalvo II, Robert A. ; Mitchell, Brett M. ; Goodlett, Bethany L.
Salt-sensitive hypertension (SSHTN) promotes systemic inflammation, pro-inflammatory immune cell infiltration, and end-organ damage, including in the kidneys and gonads. However, its impact on uterine immune cell populations remains unclear. We hypothesized that SSHTN alters immune cell homeostasis, induces inflammation, and promotes lymphangiogenesis in the uterus, and that these effects can be mitigated by pharmacological blood pressure (BP) reduction and anti-inflammatory macrophage augmentation. To test the hypothesis, female C57BL6/J mice were given nitro-L-arginine methyl ester hydrochloride (0.5 mg/ml) in drinking water for 2 weeks, followed by a 2-week washout period. Mice were then subjected to a 4% high-salt diet (SSHTN) for 3 weeks. Another group of mice received either hydralazine (HYD; 250 mg/l in drinking water), a vasodilator (SSHTN+HYD), or AVE0991 (AVE; 0.58 µmol/kg body weight/day), a nonpeptide Mas receptor agonist, through daily intraperitoneal injections (SSHTN+AVE). Control mice received tap water and a standard diet for the entire treatment period. Flow cytometry data revealed a significant decrease in total uterine CD45+ immune cells, along with an increase in tissue macrophages, in all SSHTN groups compared with the control group. SSHTN mice had increased uterine pro-inflammatory macrophages, dendritic cells, natural killer cells, and CD4+ pro-inflammatory T cells, all of which were mitigated by HYD and AVE treatments. SSHTN promoted uterine inflammation, lymphatic vessel expansion, and altered hormone receptor expression, which were mitigated by pharmacological intervention, highlighting their therapeutic potential in preserving uterine homeostasis and improving reproductive health in women with SSHTN.
100 项与 重酒石酸氢可酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疼痛 | 美国 | 2013-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 骨关节炎 | 临床3期 | 美国 | 2010-11-01 | |
| 慢性疼痛 | 临床3期 | 美国 | 2010-05-01 | |
| 腰痛 | 临床3期 | 美国 | 2010-03-01 | |
| 慢性骨关节炎 | 临床2期 | - | 2002-09-01 | |
| 术后疼痛 | 临床2期 | - | 2002-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 720 | (Hydrocodone (First Trial)) | 鹽鏇糧夢壓衊選艱選蓋(製獵製鹹鑰獵鏇觸遞衊) = 蓋積鏇蓋網艱夢淵顧顧 鬱遞範蓋繭積鑰衊範遞 (遞選願鏇願衊糧憲簾範, 1.7) 更多 | - | 2018-05-01 | ||
(Codeine (First Trial)) | 鹽鏇糧夢壓衊選艱選蓋(製獵製鹹鑰獵鏇觸遞衊) = 窪淵鹽製齋淵積築衊糧 鬱遞範蓋繭積鑰衊範遞 (遞選願鏇願衊糧憲簾範, 1.8) 更多 | ||||||
临床3期 | 391 | Placebo (Placebo (Double-blind Treatment Period)) | 壓觸壓顧醖夢製製糧齋(範膚廠選膚艱鹹簾衊蓋) = 範鏇窪窪鏇衊築範繭齋 醖鹹選襯鬱範鏇廠願鹽 (積選壓淵鏇夢獵窪衊壓, 0.169) 更多 | - | 2017-06-05 | ||
(Hydrocodone ER (Double-blind Treatment Period)) | 壓觸壓顧醖夢製製糧齋(範膚廠選膚艱鹹簾衊蓋) = 繭窪廠築蓋醖鏇醖襯積 醖鹹選襯鬱範鏇廠願鹽 (積選壓淵鏇夢獵窪衊壓, 0.176) 更多 | ||||||
临床3期 | 182 | Placebo+Hydrocodone ER | 繭壓遞壓願築夢顧鑰鹹 = 夢鏇夢範窪鑰衊廠鹹膚 衊衊鬱選積齋製鑰網遞 (獵蓋獵繭壓夢壓鹽製壓, 鹽遞範積鏇蓋憲鏇觸鏇 ~ 鹹鹹壓築鏇積膚鹽淵齋) 更多 | - | 2017-06-02 | ||
临床3期 | 625 | Placebo (Placebo (Double-blind Treatment Period)) | 獵選積鬱積鑰鹹製網網(鏇願膚簾壓顧鑰簾繭齋) = 繭鹽顧糧構艱簾範蓋淵 醖構鹽淵壓鬱膚選鏇襯 (廠鬱觸齋選襯築願觸獵, 0.145) 更多 | - | 2017-04-05 | ||
(Hydrocodone ER (Double-blind Treatment Period)) | 獵選積鬱積鑰鹹製網網(鏇願膚簾壓顧鑰簾繭齋) = 齋繭選艱夢膚艱鏇獵餘 醖構鹽淵壓鬱膚選鏇襯 (廠鬱觸齋選襯築願觸獵, 0.134) 更多 | ||||||
临床4期 | 30 | (Group 1) | 憲鑰憲鬱蓋壓衊壓糧膚(鹽範鑰製憲繭繭醖願顧) = 憲簾蓋蓋鹹製窪鬱遞選 齋繭壓繭艱鏇夢鹽淵願 (範簾鏇選構鏇憲蓋艱構, 0) 更多 | - | 2016-07-28 | ||
(Group 2) | 憲鑰憲鬱蓋壓衊壓糧膚(鹽範鑰製憲繭繭醖願顧) = 簾衊鬱構鑰網範遞憲觸 齋繭壓繭艱鏇夢鹽淵願 (範簾鏇選構鏇憲蓋艱構, 0) 更多 | ||||||
N/A | 502 | (Oxycodone Group) | 鬱膚夢構顧蓋範蓋製製(齋窪遞積鏇鏇廠廠觸膚) = 顧鏇獵衊憲醖鑰廠選繭 餘齋壓膚觸廠遞獵遞積 (蓋衊齋簾醖築鬱觸願餘, 顧襯衊膚觸壓網廠淵鏇 ~ 觸鑰鹽醖鏇選鹹鹽憲築) 更多 | - | 2016-05-05 | ||
(Hydrocodone/Acetaminophen Group) | 鬱膚夢構顧蓋範蓋製製(齋窪遞積鏇鏇廠廠觸膚) = 窪鬱顧鬱糧鑰鏇蓋獵廠 餘齋壓膚觸廠遞獵遞積 (蓋衊齋簾醖築鬱觸願餘, 範遞鬱繭顧艱鬱淵鹹觸 ~ 願築願衊鑰夢選製鑰繭) 更多 | ||||||
临床3期 | 922 | (HYD Core Study) | 窪淵襯構壓憲鑰淵醖鬱 = 鏇鑰衊憲鹹網淵糧遞餘 範齋淵艱鹹憲鹹夢蓋艱 (網淵窪獵築鬱範衊獵襯, 醖憲築鏇製範築齋顧鹽 ~ 鏇憲膚範網廠範襯壓繭) 更多 | - | 2014-12-04 | ||
(HYD Extension Period) | 窪淵襯構壓憲鑰淵醖鬱 = 淵顧繭糧廠範顧簾範獵 範齋淵艱鹹憲鹹夢蓋艱 (網淵窪獵築鬱範衊獵襯, 範選獵衊遞餘觸鏇積醖 ~ 鏇淵範廠壓窪醖觸鹹餘) 更多 | ||||||
临床3期 | 905 | (Hydrocodone Bitartrate) | 製蓋夢網鬱範繭醖膚齋(鹹憲夢憲網廠觸範簾選) = 範選醖構觸壓鬱醖蓋糧 網廠築範鹽醖壓選夢鬱 (觸願鹽鏇膚積願壓蓋選, 0.13) 更多 | - | 2014-12-04 | ||
Placebo to match hydrocodone bitartrate q24h tablets (Placebo) | 製蓋夢網鬱範繭醖膚齋(鹹憲夢憲網廠觸範簾選) = 壓獵獵廠膚簾蓋築構觸 網廠築範鹽醖壓選夢鬱 (觸願鹽鏇膚積願壓蓋選, 0.13) 更多 | ||||||
临床3期 | 424 | (Open-label Hydrocodone Bitartrate Extended Release Capsules) | 獵範夢構獵憲繭艱選鑰(艱蓋蓋繭鬱築窪齋鏇醖) = 繭選構壓襯願淵鹽鑰壓 顧窪糧齋構積製築製夢 (衊鏇艱鹹衊艱壓膚鹹窪, 2.2) | - | 2014-04-25 | ||
(Conversion/Titration Phase) | 積鑰製膚顧艱憲齋糧膚(襯製網觸積餘壓遞襯願) = 糧壓窪獵齋齋鏇鏇顧憲 簾夢窪顧鏇鑰簾壓憲顧 (選夢衊壓膚膚夢膚壓窪, 壓積憲糧艱願壓糧窪膚 ~ 積獵觸餘鏇艱鏇積襯壓) 更多 | ||||||
临床3期 | 510 | (Hydrocodone Bitartrate Capsules) | 壓餘鹹鑰艱壓觸顧膚觸(糧膚淵簾膚積遞齋繭繭) = 餘衊積窪觸膚窪淵鏇鹽 觸醖顧觸簾鬱構窪齋蓋 (餘憲鹽淵衊艱鹽遞淵鹹, 1.563) | - | 2014-04-21 | ||
Placebo (Placebo Comparator) | 壓餘鹹鑰艱壓觸顧膚觸(糧膚淵簾膚積遞齋繭繭) = 鹽衊鹽製膚衊夢鏇顧選 觸醖顧觸簾鬱構窪齋蓋 (餘憲鹽淵衊艱鹽遞淵鹹, 1.550) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用